Capri Holdings sold Versace, cleaned up its balance sheet, and now trades near multi-year lows. With insider buying and heavy institutional ownership, investors face a classic question: is CPRI a luxury turnaround or a fading fashion house?

Read entire article

Kosmos Energy insiders just bought millions of dollars of stock after issuing nearly 100 million new shares. Is this a turnaround signal… or a classic case of debt-driven dilution? Let’s break down the risks, the oil assets, and the “sneaky management” dilemma.

Read entire article

Asbury Automotive Group (NYSE: ABG) may be one of the most overlooked value stocks in the market. With the CEO investing over $1M of his own money and institutions owning more than 100% of the float, the setup is intriguing.

Read entire article

Harley-Davidson stock is down more than 75% from its historic highs, but insiders are buying, institutions own over 100% of the float, and short sellers are circling. Is HOG a value trap… or a contrarian opportunity ready to roar?

Read entire article

When insiders start buying stock aggressively, investors take notice. In early 2026, executives, directors, and members of the Scripps family all stepped in to buy SSP shares. The question now: is this a deep-value media turnaround or a value trap?

Read entire article

A new CEO buying $1M in shares is always interesting. But with CSX trading near all-time highs while earnings soften, investors face a classic dilemma: operational confidence vs valuation discipline.

Read entire article

SoFi just delivered its first billion-dollar quarter, record member growth, and a fresh insider buy from CEO Anthony Noto. The fintech story is evolving from speculative startup to profitable platform — but valuation and skepticism remain. Here’s the FUNanc1al breakdown of the opportunity.

Read entire article

After a sharp decline, CoStar Group (CSGP) insiders are stepping in to buy shares. With dominant commercial real estate data, rapid Homes.com growth, and strong institutional backing, investors are asking whether the market is underestimating the company’s long-term potential.

Read entire article

Insulet (PODD) just delivered 31% revenue growth and insiders are buying — yet the stock trades at 70x earnings. Is this premium medtech compounder a long-term winner or priced for perfection? Here’s the FUNanc1al breakdown.

Read entire article

$4M+ in insider buys. 18% revenue growth. Private markets expanding. Hamilton Lane may be a premium compounder trading 47% below its highs.

Read entire article